---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-035162"
form_type: "8-K"
ticker: "ALLO"
cik: "0001737287"
company_name: "Allogene Therapeutics, Inc."
filed_at: "2025-02-25T23:59:59+00:00"
generated_at: "2026-05-26T04:49:52.607506+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Allogene expands collaboration with Foresight for MRD companion diagnostic; commits $37.3M

## Summary
- Amended agreement covers MRD assay development as companion diagnostic for cema-cel in EU, UK, Canada, Australia.
- Allogene to fund approximately $37.3 million for assay development, milestone payments, and clinical sample testing.
- Parties will use commercially reasonable efforts to obtain regulatory approval for respective products.
- Each party retains ownership of its background IP and improvements; termination rights unchanged.

## SEC filing metadata
- accession: 0001193125-25-035162
- form_type: 8-K
- ticker: ALLO
- cik: 0001737287
- company_name: Allogene Therapeutics, Inc.
- filed_at: 2025-02-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737287/000119312525035162/0001193125-25-035162-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737287/000119312525035162/d926019d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-035162
- JSON: https://secwatch.observer/filing/0001193125-25-035162.json
- Plain text: https://secwatch.observer/filing/0001193125-25-035162.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.